RNA-binding protein FUS, Developmental Studies Hybridoma Bank, AFFN-FUS-5A9
What do reviewers generally think about AFFN-FUS-5A9 from Developmental Studies Hybridoma Bank?
Researchers provide limited, largely duplicate assessments of AFFN-FUS-5A9, with no reported WB, IP, or IF performance. The available data concern flow cytometry at 0.2 μg/mL in HeLa WT and FUS KO cells, showing a small right-shift in WT fluorescence versus KO and a small but detectable FUS-dependent signal. One reviewer points out that the KO population overlapped closely with the secondary-only control, indicating low background staining. Overall, the consensus is that the antibody appears to have low background and weak but detectable specificity in flow cytometry, while broader application performance remains unaddressed.
Information about this antibody
Vendor notes
User Reviews (2)
Review of: RNA-binding protein FUS, Developmental Studies Hybridoma Bank, AFFN-FUS-5A9 by pAbmAbs Data Mining
Our team has carried out an in-depth review of the published scientific literature to identify papers and reports using antibodies directed against the human RNA-binding protein Fused-in-Sarcoma, followed by extraction and evaluation of the available data to assess performance according to the pAbmAbs rating criteria.
YCharOS is conducting a large head-to-head study comparing 18 commercially available research antibodies against the human RNA-binding protein Fused-in-Sarcoma encoded by FUS.
The collection of antibodies was tested using HeLa WT and FUS KO cells in the applications WB (WT and KO cell lysates, 30 µg protein), IP (WT cell lysate), IF (WT and KO cells), and flow cytometry (WT and KO cells). Some antibodies were evaluated across multiple applications, whereas others were tested exclusively by flow cytometry, all according to YCharOS standard protocols (see reference).
Flow cytometry using AFFNFUS5A9 (0.2 μg/mL) showed a small rightshift of the fluorescence intensity distribution in WT cells relative to FUS KO cells. The KO population overlapped closely with the secondaryonly control, indicating low background staining and a small but detectable FUSdependent component in the WT signal.
0 useful
0 not usefulReview of: RNA-binding protein FUS, Developmental Studies Hybridoma Bank, AFFN-FUS-5A9 by pAbmAbs Data Mining
Our team has carried out an in-depth review of the published scientific literature to identify papers and reports using antibodies directed against the human RNA-binding protein Fused-in-Sarcoma, followed by extraction and evaluation of the available data to assess performance according to the pAbmAbs rating criteria.
YCharOS is conducting a large head-to-head study comparing 18 commercially available research antibodies against the human RNA-binding protein Fused-in-Sarcoma encoded by FUS.
The collection of antibodies was tested using HeLa WT and FUS KO cells in the applications WB (WT and KO cell lysates, 30 µg protein), IP (WT cell lysate), IF (WT and KO cells), and flow cytometry (WT and KO cells). Some antibodies were evaluated across multiple applications, whereas others were tested exclusively by flow cytometry, all according to YCharOS standard protocols (see reference).
Flow cytometry using AFFN-FUS-5A9 (0.2 μg/mL) showed a small right-shift of the fluorescence intensity distribution in WT cells relative to FUS KO cells. The KO population overlapped closely with the secondary-only control, indicating low background staining and a small but detectable FUS-dependent component in the WT signal.
We highly encourage other scientists to share their observations.
Comments
0 useful 0 not useful
Comments